Driptan, tablets 5 mg, 30 pcs.

Pharmacotherapeutic group: spasmolytic agent.
ATC: G04BD04

Pharmacological properties

Pharmacodynamics
Oxybutynin has an antispasmodic effect on detrusor smooth muscle fibers and an anticholinergic effect by blocking the action of acetylcholine on the m-cholinoreceptors of smooth muscles. These properties contribute to relaxation of the bladder detrusor. In patients with unstable bladder function, the drug increases bladder volume and decreases the frequency of spontaneous detrusor contractions.

Pharmacokinetics
. When administered orally, oxybutynin is rapidly absorbed in the gastrointestinal tract – maximum plasma concentration (Cmax) is reached in less than 1 hour and then decreases biphasically with a half-life of 2-3 hours. The maximum effect is observed within 3-4 hours, the residual effect may persist for more than 10 hours.
Equilibrium concentration is reached after 8 days of oral administration. In elderly patients with an active lifestyle, oxybutynin does not appear to accumulate and its pharmacokinetics does not differ from that of other adult patients. However, Cmax and AUC (area under the concentration-time curve) values are significantly increased in impaired elderly patients. Oxybutynin is extensively metabolized in the liver, primarily by cytochrome P450 system enzymes, in particular CYP3A4, which is found mainly in the liver and intestinal walls; metabolites also have M-cholin-blocking effects. The main route of excretion is through the kidneys. Only 0.3-0.4% of the unchanged drug is detected in the urine of rats after 24 h and 1% in the urine of dogs after 48 h. Consequently, in rats and dogs oxybutynin is almost completely metabolized

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Impact on the ability to drive and operate motor vehicles

The drug may cause drowsiness or blurred vision. Patients should refrain from driving or operating machinery unless their physical and mental abilities have not changed.

Synopsis

Contraindications

Side effects

very often (≥1/10)

Frequently

(≥1/100 to < 1/10)

Infrequent (≥1/1000 to < 1/100)

Frequency

em>unknown (cannot estimate frequency based on available data)

Infectious and parasitic diseases

diarrhea, vomiting

abdominal discomfort, anorexia, decreased appetite, dysphagia

gastroesophageal reflux, pseudo-inflammation in patients at risk (elderly patients or patients with constipation and receiving therapy with other medications that reduce intestinal motility).

Mental disorders

confusion

agitation, anxiety, hallucinations, nightmares, paranoia, cognitive impairment in elderly patients, symptoms of depression, dependence (in patients with a history of drug or addiction), disorientation, delirium/p>

Nervous system disorders

dizziness, headache, drowsiness

cognitive impairment, seizures

/td>

cardiac disorders

./td>

tachycardia, arrhythmia

injuries, intoxications and complications of manipulation

heat stroke

Visual disturbances

dry eyes

closed angle glaucoma, mydriasis, elevated intraocular pressure, blurred vision

Renal disordersRenal and urinary tract disorders

urinary retention

disorder of urination

vascular disorders

“hot flashes”>

Dermal and subcutaneous tissue disorders

dry skin

angioedema, rash, urticaria, hypohidrosis, photosensitization

Disorders of the immune system

hypersensitivity

Overdose

The symptoms of overdose with oxybutynin gradually increase from the usual CNS side effects (from anxiety and emotional agitation to psychotic behavior), circulatory disorders (“hot flashes” of blood, drop in blood pressure, circulatory failure, etc.) to respiratory failure, paralysis and coma.

The treatment in case of overdose is symptomatic:

1. Immediate gastric lavage.

2. If life-threatening anticholinergic syndrome develops, neostigmine bromide (or physostigmine) may be used in doses according to the instructions for medical use.

Symptomatic treatment in case of fever.

In case of significant agitation or irritability, 10 mg of diazepam should be given intravenously.

If tachycardia develops, intravenous propranololol should be given.

In case of urinary retention, use a catheter.

If respiratory muscle paralysis occurs, artificial lung ventilation is necessary.

Pregnancy use